artios header image

News & Events

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

9 February 2023 | Press release

Article-1-1-400×400

Scientists uncover novel DNA repair mechanism for key cancer target

7 December 2022 | Media coverage

artios header image

Benchtop Bios Podcast featuring CFO, Abid Ansari

21 September 2022 | Media coverage

Article-2-400×400

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

10 August 2022 | Press release

Benchtop Bios Podcast featuring Dr. Graeme Smith

27 July 2022 | Media coverage

Article-3-400×400

Artios Appoints Samantha Truex to Board of Directors

23 June 2022 | Press release

For press release

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

5 April 2022 | Press release

shutterstock_1184899237 4 MB

Artios attending the AACR in New Orleans 8-12 April 2022

1 April 2022 | Conferences

event

Graeme Smith, CSO and Helen Robinson, VP Biology attending the 5th Digital DDR, ATR, & PARP Summit – 25/26 January 2022

25 January 2022 | Conferences

Graeme Smith, CSO - Artios

Listen to our CEO and CSO talk at the Northland Synthetic Lethality Conference – Nov 17 2021

2 December 2021 | Conferences

niall-CEO-artios

1 2 3 … 6 Next »

© Artios Pharma 2023 | Website by Granite 5

Terms & conditions | Privacy policy | Site map